Corporate Member Merck - NEW Indication

Corporate Member Merck - NEW Indication

KEYTRUDA (Pembrolizumab)
June, 2017

Merck is pleased to announce that KEYTRUDA is now the only anti–PD-1 approved in combination with carbo/pem for the first line treatment of patients with nonsquamous metastatic NSCLC (mNSCLC) irrespective of PD-L1 expression. KEYTRUDA is also the only anti–PD-1 approved as first-line monotherapy for patients with nonsquamous and squamous mNSCLC whose tumors have high PD-L1 expression (TPS ≥50%) and are negative for EGFR and ALK genomic tumor aberrations.

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members